-$0.74 Earnings Per Share Expected for Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) This Quarter
Wall Street brokerages expect Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) to announce earnings per share of ($0.74) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Kiniksa Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.73) and the lowest estimate coming in at ($0.75). Kiniksa Pharmaceuticals posted earnings per share of ($0.51) in the same quarter last year, which indicates a negative year-over-year growth rate of 45.1%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 7th.
According to Zacks, analysts expect that Kiniksa Pharmaceuticals will report full-year earnings of ($3.47) per share for the current fiscal year, with EPS estimates ranging from ($3.54) to ($3.40). For the next financial year, analysts expect that the business will post earnings of ($3.45) per share, with EPS estimates ranging from ($3.60) to ($3.30). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.03.
A number of large investors have recently added to or reduced their stakes in the stock. First Manhattan Co. raised its stake in Kiniksa Pharmaceuticals by 68.3% in the second quarter. First Manhattan Co. now owns 63,976 shares of the company’s stock valued at $866,000 after buying an additional 25,970 shares in the last quarter. Citadel Advisors LLC increased its position in shares of Kiniksa Pharmaceuticals by 195.8% during the second quarter. Citadel Advisors LLC now owns 372,287 shares of the company’s stock worth $5,041,000 after purchasing an additional 246,442 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Kiniksa Pharmaceuticals during the second quarter worth about $474,000. Morgan Stanley increased its position in shares of Kiniksa Pharmaceuticals by 54.2% during the second quarter. Morgan Stanley now owns 60,098 shares of the company’s stock worth $814,000 after purchasing an additional 21,130 shares in the last quarter. Finally, BlackRock Inc. increased its position in shares of Kiniksa Pharmaceuticals by 14.4% during the second quarter. BlackRock Inc. now owns 1,107,091 shares of the company’s stock worth $14,990,000 after purchasing an additional 139,072 shares in the last quarter. Hedge funds and other institutional investors own 29.79% of the company’s stock.
KNSA stock traded up $0.58 during mid-day trading on Tuesday, reaching $9.99. 115,200 shares of the company’s stock were exchanged, compared to its average volume of 76,332. The company has a market cap of $514.74 million, a price-to-earnings ratio of -2.86 and a beta of -1.56. The stock’s 50 day moving average is $12.85 and its 200 day moving average is $15.45. Kiniksa Pharmaceuticals has a 12-month low of $9.08 and a 12-month high of $32.88.
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Featured Article: Growth and Income Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.